Pharming Revenue Rises 21% on Joenja Growth
The biopharmaceutical company reported third-quarter 2026 results on October 27, 2026, driven by its Joenja and RUCONEST products.
Updated on Nov. 4, 2026 in Corporate Finance
Pharming reported third-quarter 2026 total revenue of $117.6 million, up 21% year over year. Operating profit rose 89% to $29.9 million, with operating expenses flat in the quarter.
Why it matters
The results show growth from both its rare immune disorder treatment Joenja and its hereditary angioedema drug RUCONEST, even as RUCONEST faces new oral competition. Pharming's expansion of Joenja through international launches and U.S. pediatric approvals is a key driver of the company's financial performance.
Pharming's third-quarter 2026 operating profit reached $29.9 million, up 89% year over year, while cash on hand stood at $191 million at quarter end. Joenja sales of $23.8 million grew 58% year over year, with international sales generating roughly one-third of that revenue.
The players
Pharming Group N.V.
Pharming Group N.V. is a Dutch biopharmaceutical company that develops rare disease treatments, including Joenja for primary immunodeficiency and RUCONEST for hereditary angioedema.
The details
Pharming maintained over 90% of its active RUCONEST patients despite new oral competition in the hereditary angioedema market. The company also advanced its leniolisib pipeline into common variable immune deficiency, which it identifies as one of two potential billion-dollar opportunities for Joenja.
Timeline
October 27, 2026: Pharming held its third-quarter 2026 earnings call.
Third quarter 2026: Pharming reported the revenue, profit and sales growth figures.
Corporate Finance Context
Pharming's leniolisib program is extending from primary immunodeficiency into common variable immune deficiency, a pipeline expansion that the company points to as a basis for future growth. The quarter's revenue gains show that commercial expansion of Joenja is currently supporting the company's financial results.
Investors tracking Pharming can compare the reported $191 million cash position and 89% operating profit growth against future quarterly filings. The company's pipeline progress into common variable immune deficiency will shape the investment case for the leniolisib franchise.
The takeaway
Pharming's quarter shows that a rare-disease company can grow revenue and operating profit together while holding patient retention in a competitive market. Investors should watch whether these gains continue as new competitors enter.
Further reading
For more on how companies report and analyze results like these, explore Corporate Finance.
Source note: This article includes information reported by The Motley Fool.
